UPTAKE AND DIFFUSION OF PHARMACEUTICAL INNOVATIONS IN HEALTH SYSTEMS

被引：10

作者：

Atun, Rifat A. ^{[1
]}

Gurol-Urganci, Ipek ^{[1
]}

Sheridan, Desmond ^{[2
,3
,4
,5
]}

机构：

[1] Imperial Coll London, Ctr Hlth Management, Tanaka Business Sch, South Kensington Campus, London SW7 2AZ, England

[2] Imperial Coll London, Dept Natl Heart, London W2 1PG, England

[3] Imperial Coll London, Lung Inst, London W2 1PG, England

[4] St Marys Hosp, Dept Natl Heart, London W2 1PG, England

[5] St Marys Hosp, Lung Inst, London W2 1PG, England

来源：

INTERNATIONAL JOURNAL OF INNOVATION MANAGEMENT | 2007年 / 11卷 / 02期

关键词：

Diffusion of innovation; pharmaceuticals; regulatory environment;

D O I：

10.1142/S1363919607001709

中图分类号：

C93 [管理学];

学科分类号：

12 ; 1201 ; 1202 ; 120202 ;

摘要：

Multiple interacting factors influence the uptake and diffusion of medicines which are critical to improving health. However, there is a gap in our knowledge on how regulatory policies and other national health systems attributes combine to impact on the utilisation of innovative drugs, and health system goals and objectives. Our review demonstrates that strong regulation adversely affects access to innovation, reduces incentives for research-based firms to develop innovative products and leads to short-and long-term welfare losses. Short-term efficiency gains from reducing pharmaceutical expenditures may actually increase total healthcare costs, reduce user choice, and in some cases, adversely affect health outcomes. Decision makers need to adopt a holistic approach to policy making, and consider potential impact of regulations on the uptake and diffusion of innovations, innovation systems and health system goals.

引用

页码：299 / 321

页数：23

共 137 条

[31] The price of innovation: new estimates of drug development costs [J].